Health-state utilities in long-term advanced melanoma survivors comparable with the general population

M D Egeler*, L V van de Poll-Franse, R Tissier, A Rogiers, M J Boers-Sonderen, A J van den Eertwegh, G A Hospers, J W B de Groot, M J B Aarts, E Kapiteijn, D Piersma, G Vreugdenhil, A A van der Veldt, K P M Suijkerbuijk, B Neyns, K J Janssen, C U Blank, V P Retèl, A H Boekhout

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


BACKGROUND: Checkpoint inhibitors have been shown to substantially improve the survival of patients with advanced melanoma. With this growing group of survivors treated with immunotherapies, assessing their health-state utilities is essential and can be used for the calculation of quality-adjusted life years and for cost-effectiveness analyses. Therefore, we evaluated the health-state utilities in long-term advanced melanoma survivors.

METHODS: Health-state utilities were evaluated in a cohort of advanced melanoma survivors 24-36 months (N = 37) and 36-plus months (N = 47) post-ipilimumab monotherapy. In addition, the health-state utilities of the 24-36 months survivor group were assessed longitudinally, and utilities of the combined survival groups (N = 84) were compared with a matched control population (N = 168). The EQ-5D was used to generate health-state utility values, and quality-of-life questionnaires were used to establish correlations and influencing factors of utility scores.

RESULTS: Health-state utility scores were similar between the 24-36 months'- and the 36-plus months' survival group (0.81 vs 0.86; p = .22). In survivors, lower utility scores were associated with symptoms of depression (β = - .82, p = .022) and fatigue burden (β = - .29, p = .007). Utility scores did not significantly change after 24-36 months of survival, and the utilities of survivors were comparable to the matched control population (0.84 vs 0.87; p = .07).

DISCUSSION: Our results show that long-term advanced melanoma survivors treated with ipilimumab monotherapy experience relatively stable and high health-state utility scores.

Original languageEnglish
Pages (from-to)2517-2525
Number of pages9
JournalQuality of Life Research
Issue number9
Early online date20 Apr 2023
Publication statusPublished - Sept 2023

Bibliographical note

Funding Information:
This work was supported by Bristol-Myers Squibb under Protocol number CA209483. Bristol-Myers Squibb, CA209483, Annelies H Boekhout

Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG.


Dive into the research topics of 'Health-state utilities in long-term advanced melanoma survivors comparable with the general population'. Together they form a unique fingerprint.

Cite this